C12Y 402/02008
Heparin-sulfate lyase
Official title: Heparin-sulfate lyase (4.2.2.8)
C12Y402/02008 (Heparin-sulfate lyase) appears on 5 US grants and 7 published applications in this corpus.
Search patents in C12Y- Granted patents
- 5
- Published applications
- 7
- Assignees
- 10
- Inventors
- 19
- Latest grant
- 9 Feb 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 1 |
| 2021 | 1 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Treatment of retinal degeneration using gene therapy9 Feb 2021US 10,912,845 B2The University of Manchester
- Method of producing heparan sulfate having anticoagulant activity7 Jul 2020US 10,704,068 B2Ajinomoto Co., Inc.
- Agents for the prevention and/or treatment of central nervous system damage13 Feb 2018US 9,889,150 B2The University Court of the University of Glasgow
- Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria23 Jul 2002US 6,423,312 B1Insight Strategy & Marketing Ltd.
- Use of glycosaminoglycans degrading enzymes for management of airway associated diseases28 Nov 2000US 6,153,187 AInsight Strategy & Marketing Ltd.
- Treatment of retinal degeneration using gene therapy28 Oct 2021US 2021/0330812 A1The University of Manchester
- An agent, a device and a blood-circulation system for treating lysosomal storage diseases, and a method for treating lysosomal storage diseases2 Jul 2020US 2020/0206323 A1Seikagaku Corporation
- Method for mitigating metastasis16 May 2019US 2019/0144867 A1Memorial Sloan Kettering Cancer Center
- Method of Producing Heparan Sulfate Having Anticoagulant Activity18 Oct 2018US 2018/0298411 A1Ajinomoto Co., Inc.
- Treatment of retinal degeneration using gene therapy15 Dec 2016US 2016/0361437 A1The University of Manchester
Most cited
By later US patents
- Use of glycosaminoglycans degrading enzymes for management of airway associated diseases37US 6,153,187 AInsight Strategy & Marketing Ltd. · 2000
- Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria2US 6,423,312 B1Insight Strategy & Marketing Ltd. · 2002